3 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 5 Phase 1, 5 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Unknown 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Unknown 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Cantex Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma Azeliragon, Temozolomide, Radiation therapy - Glioblastoma | Early Phase 1 | Recruiting | Washington University School of Medicine | 12 | 2025-11-06 | 2026-05-29 |
| Azeliragon in MGMT Unmethylated Glioblastoma Azeliragon - Glioblastoma | Phase 2 | Active not recruiting | Cantex Pharmaceuticals | 30 | 2023-09-12 | 2026-03-31 |
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Azeliragon - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Cantex Pharmaceuticals | 30 | 2023-06-01 | 2024-06-14 |
| Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma Disulfiram, Copper Gluconate - Multiple Myeloma | Phase 1 | Terminated | University of Utah | 2 | 2021-05-21 | 2023-03-13 |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine Safety Laboratories, AE Assessment, Physical Exam - Metastatic Pancreatic Cancer | Phase 2 | Terminated | HonorHealth Research Institute | 1 | 2019-10-17 | 2023-10-18 |
| A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer Copper, Disulfiram, Copper gluconate - Prostate Cancer | Phase 1 | Terminated | Daniel George, MD | 9 | 2017-07-11 | 2021-09-16 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia CX-01, Azacitidine, Bone marrow biopsy - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 | Completed | Washington University School of Medicine | 20 | 2017-04-07 | 2019-12-05 |
| Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma Disulfiram/Copper, Temozolomide (TMZ) - Recurrent Glioblastoma | Phase 2 | Completed | Cantex Pharmaceuticals | 23 | 2017-03-09 | 2021-09-13 |
Glioblastoma (4) · Pancreatic Neoplasms (2) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Prostatic Neoplasms (1)
azeliragon (4) · Disulfiram (3) · Gluconates (3) · Temozolomide (2) · 130-nm albumin-bound paclitaxel (1) · Azacitidine (1) · Clinical Protocols (1) · Copper (1) · Gemcitabine (1) · N-desulfated,2-O,3-O-desulfated heparin (1) · Radiotherapy (1) · Restraint, Physical (1) · Surgical Procedures, Operative (1) · disulfiram-copper (1)
United States (8) · Spain (1)
Andrew Hendifar, MD (1) · Daniel George, MD (1) · Douglas Sborov, MD (1) · Gayle Jameson, ACNP-BC (1) · Jiayi Huang, M.D. (1) · Jiayi Huang, MD (1) · Peter Westervelt, M.D., Ph.D. (1) · Stephen G Marcus, MD (1)